Recent Company News

• 02:02 AM ET Dec 11, 2025
  

  BofA upgrades BIM.FP, GN.DC; downgrades ALC.SW

• 01:14 AM ET Nov 05, 2025
  

  Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis (€109.30, 0.00)

• 11:17 AM ET Nov 04, 2025
  

  Transcript Intelligence: bioMerieux Q3 Sales and Revenue Guidance (€109.40, -1.50)

• 11:16 AM ET Nov 04, 2025
  

  Transcript Intelligence: bioMerieux Q3 Sales and Revenue Themes (€109.00, -1.90)

• 11:16 AM ET Nov 04, 2025
  

  Transcript Intelligence: bioMerieux Q3 Sales and Revenue Q&A (€109.00, -1.90)

• 04:08 AM ET Nov 04, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:55 AM ET Nov 04, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:06 AM ET Nov 04, 2025
  

  bioMerieux reports Q3 revenue €948.1M vs FactSet €975.8M [5 est, €951-997M]. Lowers FY sales outlook (€110.90, 0.00)

• 02:43 AM ET Oct 22, 2025
  

  bioMerieux upgraded to buy from neutral at CIC Market Solutions (€110.10, 0.00)

• 05:09 AM ET Sep 04, 2025
  

  bioMerieux downgraded to accumulate from buy at Gilbert Dupont (timing uncertain) (€118.20, +0.30)